2024
Artificial Intelligence in Cardiovascular Clinical Trials
Cunningham J, Abraham W, Bhatt A, Dunn J, Felker G, Jain S, Lindsell C, Mace M, Martyn T, Shah R, Tison G, Fakhouri T, Psotka M, Krumholz H, Fiuzat M, O’Connor C, Solomon S, Collaboratory H. Artificial Intelligence in Cardiovascular Clinical Trials. Journal Of The American College Of Cardiology 2024, 84: 2051-2062. PMID: 39505413, DOI: 10.1016/j.jacc.2024.08.069.Peer-Reviewed Original ResearchConceptsArtificial intelligenceIntegrate AIPatient privacyClinical trialsRandomized clinical trialsClinical event outcomesCardiovascular clinical trialsIntelligenceInaccurate resultsRandomized trialsInterpreting imagesCardiovascular therapyMedical decision makingDecision makingGold standardValidity of trial resultsClinical trial operationsPrivacy
2022
Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry
Bikdeli B, Caraballo C, Trujillo-Santos J, Galanaud JP, di Micco P, Rosa V, Cusidó GV, Schellong S, Mellado M, del Valle Morales M, Gavín-Sebastián O, Mazzolai L, Krumholz HM, Monreal M, Prandoni P, Brenner B, Farge-Bancel D, Barba R, Bertoletti L, Tzoran I, Reis A, Bosevski M, Bounameaux H, Malý R, Verhamme P, Caprini J, Adarraga M, Agudo de Blas P, Aibar J, Amado C, Arcelus J, Ballaz A, Barbagelata C, Barrón M, Barrón-Andrés B, Blanco-Molina Á, Beddar Chaib F, Botella E, Buño-Ramilo B, Castro J, Chasco L, Criado J, de Ancos C, de Miguel J, del Toro J, Demelo-Rodríguez P, Díaz-Brasero A, Díaz-Pedroche M, Díaz-Peromingo J, Díaz-Simón R, Domínguez I, Dubois-Silva Á, Escribano J, Espósito F, Farfán-Sedano A, Fernández-Capitán C, Fernández-Reyes J, Fidalgo Á, Font C, Francisco I, Gabara C, Galeano-Valle F, García M, García-Bragado F, García de Herreros M, García de la Garza R, García-Díaz C, Gil-Díaz A, Giménez-Suau M, Gómez-Cuervo C, Grau E, Guirado L, Gutiérrez J, Hernández-Blasco L, Jara-Palomares L, Jaras M, Jiménez D, Jiménez R, Jiménez-Alfaro C, Jou I, Joya M, Lainez-Justo S, Lalueza A, Latorre-Díez A, Lobo J, López-Jiménez L, López-Miguel P, López-Núñez J, López-Reyes R, López-Sáez J, Lorenzo A, Madridano O, Maestre A, Marchena P, Martín del Pozo M, Martín-Martos F, Martínez-Urbistondo D, Mella C, Mercado M, Muñoz-Blanco A, Nieto J, Núñez-Fernández M, Olid-Velilla M, Otalora S, Otero R, Paredes-Ruiz D, Parra P, Parra V, Pedrajas J, Peris M, Porras J, Portillo J, Ruiz-Artacho P, Ruiz-Giménez N, Ruiz-Ruiz J, Ruiz-Sada P, Salgueiro G, Sánchez-Martínez R, Sánchez-Muñoz-Torrero J, Sancho T, Soler S, Suárez-Rodríguez B, Suriñach J, Tolosa C, Torres M, Torres-Sánchez A, Uresandi F, Valero B, Valle R, Varona J, Vázquez-Friol C, Vela L, Vela J, Villalobos A, Villares P, Zamora C, Ay C, Nopp S, Pabinger I, Engelen M, Vanassche T, Yoo H, Hirmerova J, Accassat S, Ait Abdallah N, Bura-Riviere A, Catella J, Couturaud F, Crichi B, Debourdeau P, Espitia O, Falvo N, Grange C, Helfer H, Lacut K, Le Mao R, Mahé I, Morange P, Moustafa F, Poenou G, Sarlon-Bartoli G, Suchon P, Quere I, Nikandish R, Braester A, Kenet G, Basaglia M, Bilora F, Bortoluzzi C, Brandolin B, Ciammaichella M, Corgna C, de Angelis A, Imbalzano E, Mastroiacovo D, Merla S, Pesavento R, Pomero F, Siniscalchi C, Tufano A, Visonà A, Vo Hong N, Zalunardo B, Kigitovica D, Rusa E, Skride A, Fonseca S, Martins-Duarte F, Meireles J. Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. JAMA Cardiology 2022, 7: 857-865. PMID: 35830171, PMCID: PMC9280612, DOI: 10.1001/jamacardio.2022.1988.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisDistal deep vein thrombosisProximal DVTLong-term outcomesPulmonary embolismVein thrombosisPostthrombotic syndromeCohort studyClinical presentationLower riskIsolated Distal Deep Vein ThrombosisProximal deep vein thrombosisEnfermedad TromboEmbólica (RIETE) registryLower comorbidity burdenUpper extremity DVTInternational cohort studyMultivariable adjusted analysesOptimal long-term managementRandomized clinical trialsAnalysis of patientsCOVID-19 infectionLong-term managementAsymptomatic DVTComorbidity burdenInfrapopliteal veinsEfficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patients
2021
Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States
Sangha V, Lipska K, Lin Z, Inzucchi SE, McGuire DK, Krumholz HM, Khera R. Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States. Circulation Cardiovascular Quality And Outcomes 2021, 14: e008381. PMID: 34779654, PMCID: PMC9022137, DOI: 10.1161/circoutcomes.121.008381.Peer-Reviewed Original ResearchConceptsType 2 diabetesMedicare beneficiariesSodium-glucose cotransporter 2 inhibitorsLarge randomized clinical trialsMedicare Part D prescriber dataChronic kidney diseaseCotransporter 2 inhibitorsAtherosclerotic cardiovascular diseasePercent of cliniciansRandomized clinical trialsUS Medicare beneficiariesAdvanced practice providersCross-sectional studyKidney outcomesSGLT2i useSulfonylurea prescriptionUnique cliniciansCardiovascular deathMedication classesKidney diseaseLabel indicationsClinical trialsSGLT2iCardiovascular diseasePractice providers
2020
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, Londhe A, Cho J, Park J, Schuemie M, Suchard MA, Madigan D, Hripcsak G, Gupta A, Reich CG, Ryan PB, Park RW, Krumholz HM. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA 2020, 324: 1640-1650. PMID: 33107944, PMCID: PMC7592033, DOI: 10.1001/jama.2020.16167.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAdultAgedAged, 80 and overAlgorithmsAspirinCase-Control StudiesCause of DeathClopidogrelDatabases, FactualDyspneaFemaleHemorrhageHumansIschemiaMaleMiddle AgedMyocardial InfarctionNetwork Meta-AnalysisPercutaneous Coronary InterventionPropensity ScorePurinergic P2Y Receptor AntagonistsRecurrenceRepublic of KoreaRetrospective StudiesStrokeTicagrelorUnited StatesConceptsNet adverse clinical eventsAcute coronary syndromePercutaneous coronary interventionAdverse clinical eventsHemorrhagic eventsIschemic eventsHazard ratioCause mortalityCoronary syndromeCoronary interventionClinical eventsRisk of NACEClinical practiceLarge randomized clinical trialsPrimary end pointRetrospective cohort studyPropensity-matched pairsSummary hazard ratioRandomized clinical trialsRoutine clinical practiceSignificant differencesP2Y12 platelet inhibitorsTicagrelor groupCohort studySecondary outcomes
2019
Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT
Shahu A, Herrin J, Dhruva SS, Desai NR, Davis BR, Krumholz HM, Spatz ES. Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT. Journal Of The American Heart Association 2019, 8: e012277. PMID: 31362591, PMCID: PMC6761647, DOI: 10.1161/jaha.119.012277.Peer-Reviewed Original ResearchConceptsBlood pressure controlLow-income sitesCardiovascular outcomesPressure controlALLHAT participantsPoor blood pressure controlEnd-stage renal diseaseHospitalization/mortalityAdverse cardiovascular eventsCardiovascular risk factorsWorse cardiovascular outcomesHigh blood pressureStandardized treatment protocolRandomized clinical trialsBackground Observational studiesLow socioeconomic statusHighest income quintileAngina hospitalizationCardiovascular eventsCause mortalityCoronary revascularizationClinical characteristicsBlood pressureRenal diseaseClinical outcomes
2017
Impact of Telemonitoring on Health Status
Jayaram NM, Khariton Y, Krumholz HM, Chaudhry SI, Mattera J, Tang F, Herrin J, Hodshon B, Spertus JA. Impact of Telemonitoring on Health Status. Circulation Cardiovascular Quality And Outcomes 2017, 10: e004148. PMID: 29237746, PMCID: PMC5776725, DOI: 10.1161/circoutcomes.117.004148.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy QuestionnaireUsual careHealth statusHeart failureKCCQ overall summary scoreRecent heart failure hospitalizationDisease-specific health statusKCCQ overall summaryHeart failure hospitalizationWeeks of dischargeRandomized clinical trialsOverall summary scoreKCCQ scoresNoninvasive TelemonitoringFailure hospitalizationBaseline characteristicsSecondary outcomesTreatment armsClinical trialsSummary scoresPatientsSubscale scoresCareHospitalizationScores
2016
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA 2016, 315: 1034-1045. PMID: 26954412, PMCID: PMC4823136, DOI: 10.1001/jama.2016.0299.BooksConceptsRandomized clinical trialsIntensive glycemic controlGlycemic controlClinical trialsOlder adultsMicrovascular outcomesTreatment burdenPatient preferencesMost RCTsLarge randomized clinical trialsType 2 diabetes mellitusMajor macrovascular eventsStandard glycemic controlOptimal glycemic controlLower treatment burdenSurrogate end pointsHigh-quality evidenceType 2 diabetesLikelihood of benefitMajority of adultsGlycemic treatmentMacrovascular eventsDiabetes mellitusPatient factorsAging Patient
2009
What Works In Chronic Care Management: The Case Of Heart Failure
Sochalski J, Jaarsma T, Krumholz HM, Laramee A, McMurray JJ, Naylor MD, Rich MW, Riegel B, Stewart S. What Works In Chronic Care Management: The Case Of Heart Failure. Health Affairs 2009, 28: 179-189. PMID: 19124869, DOI: 10.1377/hlthaff.28.1.179.Peer-Reviewed Original ResearchConceptsCare management programChronic care managementCare managementChronic care management programEvidence baseRoutine care patientsRandomized clinical trialsReadmission daysCare patientsHeart failureHospital readmissionClinical trialsPatient outcomesMulti-disciplinary teamHealth plansProgram delivery methodsPatientsImportant guidepostsManagement programDelivery methodsReadmissionTrials
2007
Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials
Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials. JAMA Internal Medicine 2007, 167: 1930-1936. PMID: 17923591, DOI: 10.1001/archinte.167.18.1930.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersSymptomatic left ventricular dysfunctionLeft ventricular dysfunctionII receptor blockersVentricular dysfunctionAdverse effectsMedication discontinuationReceptor blockersSymptomatic hypotensionRenal functionACE inhibitorsClinical trialsRelative riskEnzyme inhibitorsAngiotensin converting enzyme (ACE) inhibitorsACE inhibitor therapyHealth clinical trialsChronic heart failureRandomized clinical trialsAcute myocardial infarctionConfidence intervalsRandom-effects modelSignificant increaseEligible RCTsHeart failureResponse to Letters Regarding Article, “Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials”
Kashani A, Foody J, Wang Y, Krumholz H, Phillips C, Mangalmurti S, Ko D. Response to Letters Regarding Article, “Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials”. Circulation 2007, 116 DOI: 10.1161/circulationaha.107.697227.Peer-Reviewed Original ResearchRandomized clinical trialsStatin therapyClinical trialsRisk AssociatedTherapyTrialsSystematic overview
2006
Influenza Vaccination as Secondary Prevention for Cardiovascular Disease
Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease. Circulation 2006, 114: 1549-1553. PMID: 16982936, DOI: 10.1161/circulationaha.106.178242.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseSecondary preventionCardiovascular conditionsInfluenza vaccination coverage levelsInfluenza vaccination coverage ratesComprehensive secondary preventionAtherosclerotic vascular diseaseVaccination coverage ratesRandomized clinical trialsAmerican Heart AssociationVaccination coverage levelsCardiovascular morbidityCause mortalityInfluenza immunizationInfluenza vaccinationCohort studyInfluenza seasonInfluenza vaccineHeart AssociationAnnual vaccinationVascular diseaseClinical trialsAmerican CollegeCardiology practiceAttenuated vaccinesInfluenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology
Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, Dunbar S, Krumholz HM. Influenza Vaccination as Secondary Prevention for Cardiovascular Disease A Science Advisory From the American Heart Association/American College of Cardiology. Journal Of The American College Of Cardiology 2006, 48: 1498-1502. PMID: 17010820, DOI: 10.1016/j.jacc.2006.09.004.Peer-Reviewed Original ResearchConceptsSecondary preventionCardiovascular diseaseCardiovascular conditionsAmerican CollegeAmerican Heart Association/American CollegeInfluenza vaccination coverage levelsInfluenza vaccination coverage ratesComprehensive secondary preventionAtherosclerotic vascular diseaseVaccination coverage ratesRandomized clinical trialsAmerican Heart AssociationVaccination coverage levelsCardiovascular morbidityCause mortalityInfluenza immunizationInfluenza vaccinationCohort studyInfluenza seasonInfluenza vaccineScience AdvisoryHeart AssociationAnnual vaccinationVascular diseaseClinical trialsStatins and Mortality Among Elderly Patients Hospitalized With Heart Failure
Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and Mortality Among Elderly Patients Hospitalized With Heart Failure. Circulation 2006, 113: 1086-1092. PMID: 16490817, DOI: 10.1161/circulationaha.105.591446.Peer-Reviewed Original ResearchConceptsHeart failureStatin therapyElderly patientsOlder patientsCoronary artery disease statusCox proportional hazards modelCurrent HF therapiesLong-term mortalityPrimary discharge diagnosisGroup of patientsTotal cholesterol levelsRandomized clinical trialsEligible Medicare beneficiariesProportional hazards modelYears of ageHF therapyStatin useClinical characteristicsDischarge diagnosisCholesterol levelsHospital characteristicsClinical trialsPhysician specialtyTeaching hospitalStatins
2005
Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: Evidence from randomized clinical trials
Sedrakyan A, Treasure T, Browne J, Krumholz H, Sharpin C, van der Meulen J. Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia in general thoracic surgery: Evidence from randomized clinical trials. Journal Of Thoracic And Cardiovascular Surgery 2005, 129: 997-1005. PMID: 15867772, DOI: 10.1016/j.jtcvs.2004.07.042.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAmiodaroneAnti-Arrhythmia AgentsAtrial FibrillationAtrial FlutterCalcium Channel BlockersDigitalis GlycosidesEvidence-Based MedicineFemaleFlecainideHospital CostsHumansLength of StayMagnesiumMaleMiddle AgedMorbidityPostoperative ComplicationsPremedicationPreoperative CareRandomized Controlled Trials as TopicTachycardia, SupraventricularThoracic Surgical ProceduresTreatment OutcomeConceptsPostoperative atrial tachyarrhythmiasGeneral thoracic surgeryAtrial tachyarrhythmiasCalcium channel blockersRandomized clinical trialsThoracic surgeryClinical trialsSingle small trialLonger hospital stayUse of digitalisPossible adverse eventsFixed-effects modelAntiarrhythmic medicationsPharmacologic prophylaxisHospital stayProphylactic regimenAdverse eventsCommon complicationPulmonary edemaSignificant morbidityUnblinded trialCochrane DatabaseProphylactic useSmall trialsPlacebo control
2004
Systolic Hypertension in Older Persons
Chaudhry SI, Krumholz HM, Foody JM. Systolic Hypertension in Older Persons. JAMA 2004, 292: 1074-1080. PMID: 15339901, DOI: 10.1001/jama.292.9.1074.BooksConceptsSystolic blood pressureSystolic hypertensionBlood pressureOlder personsOlder patientsClinical trialsBaseline systolic blood pressureTolerance of therapyJoint National CommitteeFirst-line therapyDiastolic blood pressureHigh blood pressureCalcium channel blockersRandomized clinical trialsTreatment of patientsEnglish-language literatureLarge-scale trialsSearch terms hypertensionAntihypertensive therapyCardiovascular riskThiazide diureticsDATA EXTRACTIONPatient preferencesSeventh ReportTerm hypertension
2000
Are β-Blockers Effective in Elderly Patients Who Undergo Coronary Revascularization After Acute Myocardial Infarction?
Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Are β-Blockers Effective in Elderly Patients Who Undergo Coronary Revascularization After Acute Myocardial Infarction? JAMA Internal Medicine 2000, 160: 947-952. PMID: 10761959, DOI: 10.1001/archinte.160.7.947.Peer-Reviewed Original ResearchConceptsCoronary artery bypass surgeryPercutaneous transluminal coronary angioplastyBeta-blocker therapyAcute myocardial infarctionNonrevascularized groupCoronary revascularizationElderly patientsMyocardial infarctionNon-revascularized groupArtery bypass surgeryTransluminal coronary angioplastyClinical practice guidelinesCooperative Cardiovascular ProjectRandomized clinical trialsAmerican Heart AssociationBypass surgerySuccessful revascularizationClinical factorsCoronary angioplastyHeart AssociationPotential confoundersClinical trialsPractice guidelinesRevascularizationAmerican College
1995
In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators.
Cohen D, Krumholz H, Sukin C, Ho K, Siegrist R, Cleman M, Heuser R, Brinker J, Moses J, Savage M, Detre K, Leon M, Baim D. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. Circulation 1995, 92: 2480-7. PMID: 7586348, DOI: 10.1161/01.cir.92.9.2480.Peer-Reviewed Original ResearchConceptsMedical care costsInitial hospital costsCoronary stentingVascular complicationsConventional angioplastyBalloon angioplastyCare costsInitial hospitalizationInitial stentingHospital costsPalmaz-Schatz coronary stent implantationCatheterization laboratory costsElective coronary stentingPatient's initial hospitalizationSingle coronary lesionsSubsequent hospital visitsSubsequent revascularization proceduresSymptomatic coronary diseaseCoronary stent implantationConventional balloon angioplastyRandomized clinical trialsLength of stayDetailed resource utilizationAngiographic restenosisRepeat revascularization